North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health
Key facts
- Where
- Newark, United StatesSee the site
Where in United States
- North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)Newark, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Corey DeStefano
- Trial code
- NCT07746999
- Record updated
- 5 August 2026
- Original description
Primary Objective:Read full original descriptionShow less
Primary Objective:
Assess disparities in liver health outcomes among transgender individuals on GAHT by evaluating liver function markers (transaminases, bilirubin levels, etc), as well as liver elasticity and presence of liver steatosis or Nonalcoholic Fatty Liver Disease (NAFLD) through FibroScan. A total of 60 participants will be recruited throughout the study, with a ratio of 1:1 between transgender participants who have been on GAHT more than 6 months ( = or > 182 days), and transgender participants who have been on GAHT for less than 6 months ( < 181 days) at the start of the study.
Secondary Objectives:
Assess liver health-related risk factors (e.g. obesity, alcohol consumption) in transgender population.
Investigate the association between specific hormone regimens and liver function in transgender individuals.
Explore potential modifiers of liver health outcomes, such as age, social barriers determinants of health, duration of hormone therapy and adherence to medical guidelines.
Change in Quality of Life from baseline to last study visit.
Inclusion: Transgender individuals (18 years or older); Individuals who are able to write and/or read in English. -.
Exclusion: Inability to provide informed consent; Individuals with known decompensated liver cirrhosis.